Her2-receptor negative breast cancer

This study tests whether giving fluzoparib (a PARP inhibitor) together with camrelizumab (an immunotherapy) before surgery can make HER2-negative breast cancer disappear completely in people with an inherited BRCA mutation. The trial enrolls 64 patients with early or locally adva…

This study compares two treatments for people with high-stage, estrogen-positive, HER2-negative breast cancer that has a low genetic risk of returning. One group gets standard hormone therapy plus a targeted pill (ribociclib), while the other gets chemotherapy first, then the sam…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This Phase 2 trial is testing a new drug called denikitug, alone or combined with other cancer drugs, in 120 people with advanced HER2-negative stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. The main goal is to see if the drug …

This phase III trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can prevent breast cancer from returning in people with a specific high-risk type of hormone receptor-positive, HER2-negative breast cancer. About 3,680 participants with sta…

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with various types of breast cancer (…

This Phase 3 trial tests whether elacestrant, a new hormone therapy, can prevent distant metastasis better than standard hormone therapies in 220 patients with ER+/HER2- breast cancer whose blood tests show signs of cancer DNA (ctDNA) but no visible spread. Participants are rando…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…

This phase 2 trial tests whether adding cediranib or ceralasertib to olaparib can overcome resistance in BRCA-mutated advanced breast cancer. About 60 participants with HER2-negative, BRCA-positive tumors that have progressed on prior therapy will receive one of the two drug comb…

This early-phase trial is testing a new drug called BGB-21447, which blocks a protein that helps cancer cells survive. It is given together with standard hormone therapy (fulvestrant) and sometimes another targeted drug (BGB-43395). The study involves 120 adults with HR+/HER2- me…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This study is testing many different drug combinations in people with metastatic breast cancer that has spread or cannot be removed by surgery. Researchers are looking at which combinations work best for different cancer types, such as triple-negative or hormone receptor-positive…

This phase 2 trial is testing whether adding a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) to elacestrant works better than elacestrant alone for people with advanced ER+/HER2- breast cancer that has already been treated with a CDK4/6 inhibitor. The study will enro…

This study tests whether giving a different antibody-drug conjugate (ADC) to people with advanced breast cancer who have already tried an ADC can still shrink tumors or slow the disease. About 160 participants will receive one of several ADCs or a targeted pill. The goal is to se…

This trial tests whether time-restricted eating (TRE) — a 16:8 fasting schedule — is feasible for patients with HER2-negative breast cancer undergoing neoadjuvant chemotherapy. Participants will follow TRE for 16 weeks while receiving chemo, and researchers will measure how many …

This study compares two drug combinations for people with a type of advanced breast cancer (HR+/HER2-) that has a specific genetic change (PIK3CA mutation) and has worsened after prior treatment. About 540 adults will receive either the experimental drug RLY-2608 plus fulvestrant…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in 40 adults with advanced breast cancer that has no HER2 protein (HER2-0). Participants get the drug every 3 weeks. The goal is to see if it shrinks tumors and which patients benefit most.

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This early-phase study tests a new drug, ASP2998, that targets a protein called TROP2 found on many solid tumors. The drug is given alone or with standard treatments like pembrolizumab or carboplatin. The main goals are to check safety and find the right dose. About 428 adults wi…

This phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…

This phase 1 trial tests whether adding the experimental antibody axatilimab to the standard drug olaparib is safe and tolerable for people with HER2-negative breast cancer that has spread and is linked to BRCA1, BRCA2, or PALB2 gene changes. Researchers will enroll about 20 part…

This study compares a combination of two drugs (elacestrant and capecitabine) to capecitabine alone in people with advanced estrogen receptor-positive breast cancer that no longer responds to CDK 4/6 inhibitors. About 297 participants will be randomly assigned to one of the two t…

This phase 2 trial is testing two antibody-drug conjugates—trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan (Dato-DXd)—in people with HER2-negative metastatic breast cancer whose disease has worsened after prior antibody-drug conjugate therapy. Participants will receiv…

This study tests a device called TheraBionic P1 that sends low-level electromagnetic fields to the body. It is for people with advanced hormone-positive, HER2-negative breast cancer who have already tried standard treatments. The goal is to see if the device can help control the …

This study tests different hormone therapies in men with breast cancer before they have surgery. The goal is to see which treatment works best to shrink the tumor. About 60 men with hormone receptor-positive breast cancer will take part.

This study tests whether adding everolimus to elacestrant can help people with a certain type of advanced breast cancer (ER+/HER2- with an ESR1 mutation) live longer without their cancer getting worse. About 240 adults whose cancer has stopped responding to standard hormone thera…

This phase 2 trial is testing whether the combination of utidelone and capecitabine can shrink brain tumors in people with HER2-negative breast cancer that has spread to the brain. About 120 participants will receive either utidelone alone or with capecitabine. The main goal is t…

This phase II trial tests two drugs, imlunestrant and abemaciclib, in 42 people with ER+ breast cancer who have tiny amounts of cancer DNA still in their blood after initial treatment. The goal is to see if the combination can clear these leftover cancer cells. Participants will …

This study looks at how well sacituzumab tirumotecan (SKB264) works, either alone or with other treatments, in people with advanced HER2-negative breast cancer that has spread or come back. It includes two groups: those with triple-negative breast cancer and those with hormone re…

This phase 3 trial is testing a new drug called palazestrant (OP-1250) combined with ribociclib against the standard letrozole plus ribociclib for people with ER+, HER2- advanced breast cancer who haven't had prior treatment. About 1,000 participants will be randomly assigned to …

This Phase 2 trial is testing whether the drug sacituzumab govitecan (Trodelvy) can shrink tumors in people with a specific type of advanced breast cancer (HR+/HER2 low or ultra low) who have already received another targeted drug called T-DXd. The study will enroll 75 participan…

This study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …

This phase 2 trial tests whether giving the chemotherapy drug capecitabine in a flexible, response-based way (adaptive therapy) can better control metastatic ER-positive breast cancer. About 35 adults with advanced, hormone-resistant disease will receive doses that are adjusted b…

This Phase 2 trial tests an oral form of the chemotherapy drug paclitaxel, taken daily or three times a week, for people with advanced HER2-negative breast cancer. The study first finds the best dose of the oral pill alone, then combines it with the immunotherapy toripalimab to s…

This phase 2 trial is testing whether the investigational drug datopotamab deruxtecan (Dato-DXd) can safely and effectively treat HER2-negative breast cancer that has spread to the brain. The study enrolls adults with metastatic breast cancer who have brain metastases that are ei…

This phase 3 study tests whether adding capivasertib to standard hormone therapy helps people with HR+/HER2- advanced breast cancer stay on treatment longer and maintain quality of life. About 250 adults whose cancer worsened after prior hormone therapy will take capivasertib plu…

This trial is testing whether combining an antibody called naxitamab, the chemotherapy drug gemcitabine, and specially engineered natural killer (NK) cells from a healthy donor can safely shrink tumors in people with advanced HER2-negative breast cancer that has spread. The cance…

This early-phase trial is testing an experimental oral drug called RGT-490 in about 63 adults with advanced solid tumors (including certain breast, ovarian, and endometrial cancers) that have a PIK3CA gene mutation and have stopped responding to standard treatments. The main goal…

This early-phase trial is testing a personalized vaccine made from each patient's unique tumor mutations. The vaccine is given along with an immune booster (poly ICLC) to help the body's T cells attack the cancer. The study includes up to 25 adults with advanced melanoma, breast …

This study tests two experimental drugs, AK146D1 and AK112, given together to people with advanced breast cancer that has spread or come back. The goal is to see if the combination is safe and can shrink tumors or slow the disease. About 200 adults aged 18 to 75 with HER2-negativ…

This phase 2 study is testing a drug called sacituzumab govitecan, alone or with pembrolizumab, given before surgery to people with localized triple-negative breast cancer. The goal is to see if these drugs can eliminate all cancer cells in the breast and lymph nodes before surge…

This trial investigates whether adding simvastatin, a widely used cholesterol medication, to the standard hormone therapy letrozole can better slow the growth of hormone receptor-positive, HER2-negative breast cancer before surgery. About 40 adults with stage I-III breast cancer …

This study is for people with a type of breast cancer (hormone receptor-positive, HER2-negative) that has come back in the same area after initial treatment. The goal is to see if adding the drug ribociclib to standard hormone therapy can help prevent the cancer from returning ag…

This phase II trial tests whether combining three experimental antibody-drug conjugates (SHR-A1811, SHR-A1921, and SHR-A2102) with the immunotherapy drug adebrelimab can shrink tumors in people with HER2-negative advanced breast cancer. Participants must have already tried at lea…

This phase 2 trial tests a personalized approach for early-stage, hormone receptor-positive breast cancer. Participants receive a combination of CDK4/6 inhibitors and endocrine therapy before surgery. A blood test (ctDNA) is used to monitor tumor DNA and may help decide if chemot…

This study tests whether a blood test (ctDNA) can identify women with early-stage, hormone-positive breast cancer who can safely avoid chemotherapy. Instead of chemo, they receive a targeted pill (dalpiciclib) plus hormone therapy before surgery. The goal is to reduce side effect…

This early-stage trial is testing a new drug called sigvotatug vedotin, alone or with other cancer medicines, in people with advanced solid tumors like lung, head and neck, and breast cancers. The study aims to find a safe dose and check for side effects. About 1,000 participants…

This phase 2 trial is testing whether a simple blood test that looks for tumor DNA (ctDNA) can help doctors decide when to switch treatments in people with metastatic triple-negative breast cancer. The study compares standard care with a strategy where ctDNA results guide an earl…

This phase II trial is recruiting 120 women with advanced HER2-negative breast cancer to find out whether it is better to receive antibody drug conjugates (ADCs) before chemotherapy or after. Participants will be randomly assigned to one of two sequences, and researchers will com…

This study tests whether adding two immunotherapy drugs (CDX-1140 and CDX-301) to standard chemotherapy (PLD) is safe and helps control metastatic HER2-negative breast cancer. About 30 people with advanced cancer that has not responded to other treatments will take part. The goal…

This early-phase trial is testing leflunomide, a drug currently used for rheumatoid arthritis, in people with advanced solid tumors that have a PTEN gene change or HER2-negative breast cancer. The study has two parts: first, finding a safe dose and checking for side effects; seco…

This study tests whether adding an immunotherapy drug called adebrelimab to chemotherapy, with or without radiation, before surgery can help eliminate HER2-negative locally advanced breast cancer. About 170 women aged 18-70 will participate. The main goal is to see if the cancer …

This phase 2 trial tests whether adding a PD-L1 antibody (adebrelimab) to a three-drug chemotherapy regimen (vinorelbine, cyclophosphamide, capecitabine) and either early or delayed radiotherapy can help control brain tumors in people with advanced HER2-negative breast cancer. Ab…

This study tests a combination of two drugs—elacestrant and trastuzumab deruxtecan—in people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultralow) that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. The goal is to find the s…

This study looks at whether giving hormone therapy before breast-conserving surgery helps reduce leftover cancer cells at the edges of removed tissue. It involves 176 postmenopausal women with stage 2-3 ER+/HER2- invasive lobular carcinoma. The goal is to see if this approach lea…

This phase 2 trial is testing a combination of three drugs—alpelisib, L-NMMA, and nab-paclitaxel—in people with a rare, aggressive form of breast cancer called metaplastic breast cancer (MpBC) that has spread or is locally advanced. The study aims to find the best dose and see if…

This early-stage trial tests the drug abemaciclib (a CDK4/6 inhibitor) given together with targeted radiation for people with metastatic HR+ HER2- breast cancer that has spread to bone. The main goal is to find the safest dose of abemaciclib when combined with radiation. About 28…

This Phase 2 trial at Fudan University tests several targeted drug combinations given before surgery for early-stage breast cancer. The goal is to see which combinations best eliminate all signs of cancer (pathological complete response) based on each tumor's specific subtype. Ab…

This study is for people with a common type of breast cancer (ER-positive, HER2-negative) that has a moderate to high risk of coming back based on tumor size and lymph node involvement, but a low genetic risk score. Instead of chemotherapy after surgery, participants can choose t…

This early-phase trial tests a new treatment made from specially engineered cord blood cells (TROP2-CAR-NK cells) in adults with advanced solid tumors that have not responded to standard therapies. The main goal is to find a safe dose and monitor side effects. Up to 54 participan…

This phase 2 trial is testing whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab, together called QL1706) plus standard chemotherapy can help people with advanced HER2-negative stomach cancer that has low PD-L1 levels. The study will enroll 77 particip…

This phase 2 trial is testing whether adding low or high dose radiation to standard chemotherapy and the immunotherapy drug pembrolizumab can improve treatment for people with node-positive triple negative breast cancer. Thirty-two participants will be randomly assigned to receiv…

This phase 2 trial is testing whether the drug elacestrant, given alone or with triptorelin (which temporarily stops ovary hormone production), can slow or shrink hormone-sensitive breast tumors in premenopausal women. About 96 women will take the pills daily for 30 days before t…

This pilot study is testing whether a device called TheraBionic P1, which delivers targeted electromagnetic fields, can affect breast cancer tumors before surgery. About 24 women with early-stage, hormone receptor-positive, HER2-negative breast cancer will use the device three ti…

This study tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy can help shrink tumors or slow disease in people with advanced HER2-negative breast cancer. About 92 adults whose cancer has worsened after prior treatments will receive the combinat…

This study looks at whether giving a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) can work well and cause fewer side effects in women aged 65 and older with early-stage HER2-negative breast cancer. The goal is to help these women complete their treatment …

This study is testing a combination of two drugs, utidelone and bevacizumab, in people with advanced HER-2 negative breast cancer who have already tried at least two other treatments. The goal is to see if this combination can slow down the cancer's growth and improve outcomes. A…

This study tests a combination of two drugs, eribulin and anlotinib, for people with HER2-negative breast cancer that has spread or come back. Participants have already tried other treatments without success. The goal is to see if this combo can slow cancer growth and improve sur…

This study tests a vaccine called STEMVAC in people with hormone receptor-positive, HER2-negative breast cancer that has spread. The vaccine is designed to help the immune system attack cancer cells. Participants will receive STEMVAC along with their usual hormone therapy, a targ…

This study tests a new oral drug called INX-315 in 150 people with advanced breast cancer, ovarian cancer, or other solid tumors that have not responded to standard treatments. The drug is given alone or combined with other cancer drugs (fulvestrant or abemaciclib). The goal is t…

This phase 2 trial is testing whether turkey tail mushroom extract can slow or shrink estrogen receptor-positive, HER2-negative breast cancer in post-menopausal women. Forty participants will take the supplement between diagnosis and surgery, and researchers will measure changes …

This study tests whether a combination of three drugs (anastrozole, fulvestrant, and abemaciclib) can shrink or control tumors in people with a common type of advanced breast cancer (hormone receptor positive, HER2-negative). About 20 participants whose cancer has spread or retur…

This study is for people with certain types of breast cancer (HER2-positive or triple-negative) who have a complete response to initial drug therapy. It tests whether they can safely skip surgery and only receive radiation, or skip radiation if surgery shows no cancer left. For a…

This study tests a combination of two drugs, tucatinib and trastuzumab, in people with a specific type of advanced breast cancer that has a mutation in the HER3 gene. The cancer must be HER2-negative and has already been treated with at least two prior chemotherapies. The goal is…

This phase 2 trial is testing a combination of anti-HER2 drugs (trastuzumab emtansine, pertuzumab, and docetaxel) plus hormone therapy (tamoxifen or letrozole) given before and after surgery in 74 Nigerian women with HER2-positive breast cancer. The main goal is to see if the can…

This study is testing whether adding two drugs (anlotinib and a tubulin inhibitor) to standard radiation therapy can help control HER2-negative breast cancer that has spread to the brain. About 39 women aged 18-70 will receive radiation followed by the drug combination. The main …

This early-phase study tests an experimental vaccine made from a patient's own immune cells, designed to target two cancer-related proteins (HER2 and HER3). The vaccine is injected directly into the tumor alongside standard chemotherapy before surgery. The goal is to find the saf…

This study tests a new drug called SPR1020 in adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to target cancer cells with specific genetic changes (BRCA or HRR mutations) and may also reach brain tumors. The goal is to find a…

This study tests whether a blood test that tracks tumor DNA (ctDNA) can help doctors decide when to intensify treatment for HER2-negative metastatic breast cancer. All 122 participants start with antibody-drug conjugate (ADC) therapy. After two cycles, those whose disease hasn't …

This early-stage trial is testing a combination of two chemotherapy drugs (melphalan and BCNU) plus vitamins B12b and C, followed by an infusion of the patient's own stem cells. The goal is to see if this approach is safe for people with metastatic pancreatic or breast cancer, es…

This study tests a combination of two drugs, fulvestrant and abemaciclib, for people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to a first-line treatment called a CDK4/6 inhibitor. The goal is to see if taking a break fr…

This Phase I trial is testing a new drug called BL-M17D1 in 20 people with advanced breast cancer (HER2-positive or negative) or other solid tumors that have spread. The main goals are to check the drug's safety, find the right dose, and see early signs of whether it shrinks tumo…

This study tests whether tirzepatide, a drug used for weight loss, can help patients with early-stage hormone receptor-positive, HER2-negative breast cancer lose at least 5% of their body weight during adjuvant treatment. The trial will enroll 40 adults and also check safety, sid…

This early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug…

This phase 2 trial is testing whether a combination of two drugs, neratinib and capecitabine, can help people with HER2-negative breast cancer that has spread to the brain. The study enrolls 22 adults whose tumors show abnormal HER2 activity on a special test. Researchers will me…

This study tests whether adding bevacizumab to standard chemotherapy before surgery can improve outcomes for people with early or locally advanced HER2-negative breast cancer. About 75 participants will receive the drug combination, and researchers will measure how many achieve a…

This study is for people with HER2-negative breast cancer that has spread to the lining of the brain (leptomeningeal metastasis). It compares standard chemotherapy given through the veins or by mouth to the same treatment plus extra chemotherapy delivered directly into the spinal…

This study tests whether adding retinoic acid (a vitamin A derivative) to an immune checkpoint inhibitor can help shrink tumors or slow disease progression in people with HER2-negative breast cancer whose cancer stopped responding to prior immunotherapy. About 10 participants wil…

This early-phase trial is testing a radioactive drug called 177Lu-CTR-FAPI in 4 people with advanced pancreatic cancer that has not responded to standard treatments. The drug is given intravenously every 6 weeks for up to 4 doses. Researchers are checking for safety, how much rad…

This study tests whether giving radiation again after a second lumpectomy is safe for women with a common type of breast cancer (ER+HER2-). About 114 women who had radiation before and whose cancer came back at least 18 months later will receive targeted radiation over 3 weeks. T…

This phase II trial tests two experimental drugs, SI-B003 and BL-B01D1, in people with advanced HER2-negative breast cancer that has not responded to standard treatments. The study will see if the drugs can shrink tumors and determine the best dose. About 58 participants will rec…

This early-stage study is testing a new drug called RLY-2608, which is designed to block a specific mutant protein (PIK3CA) that helps some cancers grow. The trial includes people with advanced solid tumors or breast cancer that has not responded to other treatments. Participants…

This study tests a new drug called JSKN016, given with chemotherapy or immunotherapy, for people with HER2-negative breast cancer that cannot be removed by surgery or has spread. The trial includes 180 adults in China and aims to see if the combination shrinks tumors and how safe…

This study tests whether giving a single dose of radiation during breast-conserving surgery works as well as standard weeks-long radiation for early-stage, HER2-negative breast cancer. About 620 women aged 55 and older will take part. The goal is to see if this approach lowers th…

This early-phase study tests a new oral drug called SYN818 combined with olaparib in 110 adults with advanced solid tumors, including ovarian and breast cancers that have BRCA mutations or related DNA repair problems. The main goals are to find a safe dose and check for side effe…

This study is testing whether a new type of PET scan (TROP2-PET) can predict how well certain targeted drugs work in people with advanced HER2-negative breast cancer. The drugs, called antibody-drug conjugates, deliver chemotherapy directly to cancer cells. The study will enroll …

This study tests a new imaging system that uses light to monitor how breast cancer responds to chemotherapy before surgery. Researchers want to see if it can accurately predict when the cancer is completely gone. The study involves 15 women with specific types of breast cancer. I…

This study tests whether a 10-week stress reduction program is doable and helpful for people with triple negative breast cancer. The program includes relaxation, coping skills, and social support, and also addresses basic needs like utilities or transportation. Researchers will m…

This study tracks how patients with metastatic triple-negative breast cancer feel during treatment with sacituzumab govitecan or standard chemotherapy. Researchers will measure changes in quality of life and symptoms using patient questionnaires. The goal is to see which treatmen…

This study tests whether in-person acupuncture or virtual acupressure can prevent joint pain caused by aromatase inhibitors, a common hormone therapy for breast cancer. It focuses on Non-Hispanic Black women with early-stage breast cancer, who are more likely to stop treatment du…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

Researchers are studying whether blood and tissue samples can show when metastatic breast cancer stops responding to standard first-line treatment with an aromatase inhibitor and a CDK4/6 inhibitor. The study enrolls women with ER-positive, HER2-negative metastatic breast cancer …

This French study is following 126 people with HER2-negative early breast cancer who are starting olaparib as part of their treatment. Researchers want to see how many patients finish the full 12-month course in real-world settings, not just in clinical trials. The study also loo…

This study is testing whether a special PET/CT scan that looks for a protein called PSMA can help predict resistance to anti-androgen therapy in people with a specific type of metastatic breast cancer (HER2-negative, AR-positive). About 13 participants will receive an injection o…

This study is looking at whether a blood test called DiviTum TKa can predict when hormone-receptor-positive, HER2-negative metastatic breast cancer stops responding to treatment. About 100 participants will give blood samples before and during their standard therapy. The goal is …

This early-phase study looks at whether adding dapagliflozin, a diabetes drug, to standard chemotherapy changes insulin-related markers in the blood. It involves 20 women with early-stage HER2-negative breast cancer who also have high insulin levels. The goal is to gather safety …

This study aims to understand why some breast cancer patients experience 'chemobrain'—problems with memory, concentration, and thinking after chemotherapy. Researchers will track 50 patients before, during, and after chemo using brain scans, blood tests, and thinking tests. They …

This study is testing new drug combinations for breast cancer to see which ones work best for different tumor types. It involves up to 5,000 people with early-stage or locally advanced breast cancer. Researchers use MRI scans and tissue samples before surgery to predict treatment…

This study tests whether a special type of PET scan (FFNP-PET/CT) can predict how well a drug combination (abemaciclib plus hormone therapy) works in people with advanced hormone receptor-positive, HER2-negative breast cancer. About 60 participants with metastatic or locally adva…

This study tests whether a decision aid and training for surgeons can help women aged 70 and older with low-risk stage I breast cancer make better treatment choices. About 402 participants will be split into two groups: one where surgeons get shared decision-making training and p…

This study is testing whether using simple blood tests to decide when to do scans is as effective as the usual approach of regular scans for people with advanced breast cancer. About 739 participants will be randomly assigned to either blood test monitoring or standard care. The …

This study is looking at a genomic test called EndoPredict that analyzes tumor genes to predict the risk of breast cancer returning. The goal is to see if women with a low-risk score can safely skip chemotherapy and only take hormone therapy. Researchers will follow 1,000 patient…

This study will follow 319 women with early-stage, hormone-sensitive, HER2-negative breast cancer to see how well they take their prescribed aromatase inhibitors, with or without the added drug abemaciclib. Researchers will measure adherence using pill counts and questionnaires a…

This study looks at whether the number of steps breast cancer patients take each day, tracked by a smartwatch, is linked to how well their treatment works. About 82 women with non-metastatic HER2-negative breast cancer will wear a Huawei Fit 2 smartwatch during chemotherapy befor…

This study is collecting tumor and blood samples from 120 people with advanced, HER2-negative breast cancer who have a BRCA1/2 mutation. Researchers want to see if certain DNA repair proteins (POLQ, Shieldin complex, 53BP1) can predict whether a tumor will resist PARP inhibitor d…

This study will review medical records of 200 patients in China with HER2-negative metastatic breast cancer who received sacituzumab govitecan. Researchers want to see how long the drug keeps cancer from growing and how well patients tolerate it. The goal is to understand real-wo…

This study follows 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their routine care. Researchers will collect blood samples and medical records to see how long the cancer stays controlled with each ADC treatmen…